GNTLF - Genetic Technologies building pathway to profitability

(NewsDirect)

Genetic TechnologiesLtd (ASX:GTG; NASDAQ:GENE) CEO Simon Morriss tells Proactive the focusover the next 18 years is putting the pathway in place to see thebusiness on track to profitability. GTG recently confirmed that itsexpanded geneType Multi-Risk Test, to include three new diseases -pancreatic cancer, melanoma and atrial fibrillation - is now availableto order in Australia, following the launch of the expanded test inthe US in March. The geneType Multi-Risk Test now performs a total ofnine individual serious disease risk assessments, all from the onesimple saliva sample and caters for people of most ethnicities overthe age of 30.

Genetic Technologies is a diversified molecular diagnosticscompany. A global leader in genomics-based tests in health, wellnessand serious disease through its geneType and EasyDNA brands. GTGoffers cancer predictive testing and assessment tools to helpphysicians to improve health outcomes for people around the world. Thecompany has a proprietary risk stratification platform that has beendeveloped over the past decade and integrates clinical and geneticrisk to deliver actionable outcomes to physicians and individuals.Leading the world in risk prediction in oncology, cardiovascular andmetabolic diseases, Genetic Technologies continues to develop riskassessment products.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.